Annals of Oncology Advance Access originally published online on September 15, 2005
Annals of Oncology 2005 16(12):1921-1927; doi:10.1093/annonc/mdi400
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
© 2005 European Society for Medical Oncology
Darbepoetin alfa for the treatment of anemic patients with low- and intermediate-1-risk myelodysplastic syndromes
1 Department of Medical Sciences, Regina Apostolorum Hospital, Albano Laziale; 2 Department of Hematology, University of Rome ‘Tor Vergata’, S. Eugenio Hospital, Rome; 3 Department of Oncology, INI, Grottaferrata; 4 Department of Complementary Oncology, IFO – Regina Elena Institute, Rome, Italy
* Correspondence to: Dr R. Stasi, Department of Medical Sciences, ‘Regina Apostolorum’ Hospital, Via S. Francesco 50, 00041 Albano Laziale, Italy. Tel: +39-06-932989; Fax: +39-06-233231809; E-mail: roberto.stasi{at}uniroma2.it
Background: The hematological and quality of life (QoL) changes associated with darbepoetin alfa (DA) therapy were assessed in anemic patients with previously untreated low- and intermediate-1-risk myelodysplastic syndrome (MDS).
Patients and methods: Fifty-three patients received DA administered subcutaneously once a week for 24 weeks. Treatment was initiated at 150 µg fixed dose and was doubled if after the first 12 weeks there was no or suboptimal erythroid response.
Results: The final response rate was 24/53 (45%), with 21 major and three minor responses. Most of the responses (21/24; 87.5%) were obtained at the dose of 150 µg. With a median follow-up of 9.4 months, 17 patients maintain their response. Treatment was well tolerated with no relevant side-effects. MDS progression was observed in one case. Increases in hemoglobin levels were positively correlated with improved QoL scores using both the linear analog scale assessment (energy level, r = 0.429, P = 0.036; daily activities, r = 0.653, P < 0.001; overall well-being, r = 0.457, P = 0.024) and the Functional Assessment of Cancer Therapy-Anemia questionnaire (r = 0.247, P = 0.025). In multivariate analysis, only low levels (<200 IU/l) of endogenous erythropoietin predicted response to DA therapy.
Conclusions: DA is an active, safe and well tolerated treatment for anemia in a substantial proportion of patients with low- and intermediate-1-risk MDS, and has a positive impact on the patients' QoL.
Key words: anemia, darbepoetin alfa, erythropoietin, myelodysplastic syndrome, predictive factors
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  R. M. Stone How I treat patients with myelodysplastic syndromes Blood, June 18, 2009; 113(25): 6296 - 6303. [Full Text] [PDF]
|
|
|
|
 |
|
 M. Jadersten, L. Malcovati, I. Dybedal, M. Giovanni Della Porta, R. Invernizzi, S. M. Montgomery, C. Pascutto, A. Porwit, M. Cazzola, and E. Hellstrom-Lindberg Erythropoietin and Granulocyte-Colony Stimulating Factor Treatment Associated With Improved Survival in Myelodysplastic Syndrome J. Clin. Oncol., July 20, 2008; 26(21): 3607 - 3613. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. D. Ross, I. E. Allen, C. A. Probst, B. Sercus, S. M. Crean, and G. Ranganathan Efficacy and Safety of Erythropoiesis-Stimulating Proteins in Myelodysplastic Syndrome: A Systematic Review and Meta-Analysis Oncologist, October 1, 2007; 12(10): 1264 - 1273. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. F. Bunn New agents that stimulate erythropoiesis Blood, February 1, 2007; 109(3): 868 - 873. [Abstract] [Full Text] [PDF]
|
|